PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1799106
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1799106
Asthma Disease
Global Asthma Disease Market to Reach US$39.2 Billion by 2030
The global market for Asthma Disease estimated at US$26.2 Billion in the year 2024, is expected to reach US$39.2 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Pediatrics, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.9 Billion by the end of the analysis period. Growth in the Adults segment is estimated at 4.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$7.1 Billion While China is Forecast to Grow at 11.2% CAGR
The Asthma Disease market in the U.S. is estimated at US$7.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.3 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.
Global Asthma Disease Market - Key Trends & Drivers Summarized
How Is the Global Understanding of Asthma Evolving with Scientific Advances and Epidemiological Trends?
Asthma, a chronic inflammatory disease of the airways, continues to be one of the most prevalent and complex respiratory disorders globally, affecting people of all ages, geographies, and socioeconomic backgrounds. With over 300 million individuals estimated to be living with asthma worldwide, the condition represents a major public health concern. Recent advances in epidemiology and immunology have deepened the understanding of asthma as a heterogeneous disease with multiple phenotypes and endotypes, rather than a one-size-fits-all condition. This new understanding has reshaped the way asthma is diagnosed and managed, highlighting the need for personalized treatment strategies. While genetic predisposition remains a major risk factor, environmental influences such as pollution, allergens, occupational irritants, and urbanization are increasingly implicated in disease onset and exacerbation. The rise in asthma prevalence, particularly in low- and middle-income countries, reflects changing lifestyles, increased industrialization, and underdiagnosis. Asthma’s burden is not limited to physical symptoms such as wheezing, breathlessness, and coughing, but also includes psychological distress, reduced quality of life, and significant economic costs. Seasonal variations, respiratory infections, and comorbidities such as obesity and allergic rhinitis further complicate disease management. The growing body of research on asthma triggers, immune pathways, and the microbiome is paving the way for innovative diagnostic tools and targeted therapies. Despite being a manageable disease, asthma still leads to preventable hospitalizations and deaths due to disparities in access to care, inconsistent adherence to treatment, and lack of awareness. As scientific insight into the disease deepens, it is becoming increasingly clear that asthma requires a multifactorial, evidence-based, and individualized approach to effectively reduce its global impact.
What Medical and Technological Innovations Are Transforming Asthma Diagnosis and Treatment?
The management of asthma has evolved significantly with the integration of medical innovation and digital technologies that enhance early diagnosis, continuous monitoring, and targeted treatment. Traditional approaches that rely solely on inhaled corticosteroids and bronchodilators are giving way to more sophisticated treatment paradigms driven by advances in biologics, precision medicine, and digital health. Biologic therapies such as monoclonal antibodies targeting specific inflammatory pathways like IL-5, IL-4, and IgE are revolutionizing treatment for patients with severe, eosinophilic, or allergic asthma who do not respond well to conventional medications. These targeted therapies are improving outcomes by reducing exacerbation rates, improving lung function, and minimizing dependence on oral corticosteroids. On the diagnostic front, tools like fractional exhaled nitric oxide (FeNO) testing and blood eosinophil counts are helping physicians more accurately classify asthma phenotypes and adjust therapies accordingly. Portable spirometry devices and digital peak flow meters allow patients to monitor lung function at home, providing valuable real-time data that supports self-management and early intervention. The rise of mobile apps and connected inhalers with embedded sensors enables tracking of medication adherence, symptom patterns, and environmental triggers, empowering patients while providing clinicians with actionable insights. Artificial intelligence is being explored to predict exacerbations and personalize treatment plans based on historical data and real-world evidence. Smart inhalers that sync with mobile devices can alert users to missed doses or incorrect inhaler techniques, addressing two of the most common challenges in asthma care. These innovations are creating a more responsive and patient-centered care model, helping to bridge the gap between routine treatment and precision-based asthma management.
How Do Socioeconomic Factors, Lifestyle Changes, and Environmental Pressures Impact Asthma Outcomes?
Asthma outcomes are profoundly influenced by a complex interplay of socioeconomic determinants, environmental exposures, and evolving lifestyle habits that vary widely across populations and regions. In urban areas, exposure to air pollution from traffic emissions, industrial waste, and construction dust significantly increases the risk of asthma onset and exacerbation, particularly in children and the elderly. Indoor air quality, influenced by factors such as secondhand smoke, mold, and household allergens, also plays a critical role, especially in low-income settings where housing conditions may be poor. The increasing adoption of sedentary lifestyles and rising rates of obesity are emerging as contributors to poor asthma control, with research indicating a link between metabolic disorders and heightened airway inflammation. In addition, disparities in healthcare access, insurance coverage, and health literacy contribute to inconsistent diagnosis, delayed treatment initiation, and suboptimal disease control. In many developing countries, the absence of specialized respiratory care, lack of affordable medications, and limited availability of diagnostic tools hinder effective management, leading to higher rates of emergency visits and hospitalizations. Cultural beliefs and stigma surrounding chronic illnesses may also affect treatment adherence and care-seeking behavior. Climate change is adding another layer of complexity by altering pollen seasons, increasing the frequency of wildfires, and intensifying heat waves, all of which can worsen respiratory symptoms. Moreover, stress, mental health issues, and comorbid conditions such as depression and anxiety are increasingly recognized as factors that exacerbate asthma symptoms and negatively impact patient outcomes. Addressing these broader determinants of health through public policy, education, and community-based interventions is essential to reducing disparities and improving asthma care globally.
What Is Driving the Continued Global Growth of the Asthma Disease Management Market?
The growth in the asthma disease management market is driven by several converging factors, including rising disease prevalence, increasing awareness, advances in therapeutic options, and expanding use of digital health solutions. A growing global population, coupled with increased urbanization and pollution, has led to higher incidence and diagnosis rates of asthma across all age groups. Heightened public and clinical awareness has resulted in more proactive screening, especially in pediatric populations where early intervention can alter disease progression. Pharmaceutical innovations, particularly in the area of biologics and combination inhalers, are expanding the treatment arsenal, allowing for more tailored and effective interventions. The shift toward value-based healthcare is encouraging the adoption of comprehensive asthma management programs that focus on prevention, education, and adherence. Governments and health organizations are investing in public health campaigns, school-based awareness programs, and guidelines that emphasize asthma control and self-management. Insurance coverage for advanced therapies and digital tools is also becoming more widespread, making them accessible to a broader patient population. Technological advancements are enabling the development of integrated care platforms that bring together patients, providers, and payers in a coordinated ecosystem. The increasing popularity of remote care, especially post-pandemic, has accelerated the adoption of telemedicine and home-monitoring solutions for asthma. In parallel, research into the genetic and environmental underpinnings of asthma continues to yield insights that could pave the way for even more precise and preventive strategies. These diverse drivers are collectively contributing to sustained growth in the global asthma market, highlighting the need for ongoing innovation and collaboration to improve outcomes and quality of life for individuals living with this chronic respiratory condition.
SCOPE OF STUDY:
The report analyzes the Asthma Disease market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Age Group (Pediatrics, Adults)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 39 Featured) -
- AbbVie
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Circassia Pharmaceuticals
- Cipla
- GSK (GlaxoSmithKline)
- Hikma Pharmaceuticals
- Hyphens Pharma
- Janssen Pharmaceuticals (J&J)
- Mylan (now part of Viatris)
- Novartis
- Omega Pharma
- Sanofi
- Sandoz (Novartis)
- Teva Pharmaceuticals
- UCB
- Vectura Group
- Veracyte
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Asthma Disease - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Global Prevalence of Asthma Spurs Sustained Demand for Long-Term Maintenance and Rescue Therapies
- Here's How Urbanization, Pollution, and Climate Change Strengthen the Case for Expanded Asthma Diagnosis and Treatment Programs
- Increased Focus on Early Detection and Prevention Throws the Spotlight on Biomarker-Based and Digital Screening Tools
- Growing Awareness and Patient Education Initiatives Drive Higher Diagnosis Rates and Treatment Adherence
- Here's the Story: Advances in Biologic Therapies Transform Management of Severe and Eosinophilic Asthma Subtypes
- Development of Personalized Treatment Protocols Expands the Addressable Market for Genotype and Phenotype-Driven Asthma Care
- Integration of Smart Inhalers and Digital Health Platforms Enables Remote Monitoring and Data-Driven Intervention
- Expansion of Asthma Management Guidelines in Emerging Economies Fuels Growth in Inhaled Corticosteroids and Combination Inhalers
- Here's the Story: AI and Predictive Analytics Enhance Risk Stratification and Exacerbation Forecasting in Chronic Asthma Patients
- Pediatric and Geriatric Population Growth Supports Long-Term Market Opportunities Across Age Groups
- Environmental Allergen Sensitization and Indoor Air Quality Issues Drive Demand for Comprehensive Management Approaches
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Asthma Disease Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 4: World 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 7: World 16-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 10: World 16-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 11: USA Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 12: USA Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 13: USA 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- CANADA
- TABLE 14: Canada Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 15: Canada Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 16: Canada 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- JAPAN
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 17: Japan Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 18: Japan Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 19: Japan 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- CHINA
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 20: China Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: China Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 22: China 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- EUROPE
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 23: Europe Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: Europe Historic Review for Asthma Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 25: Europe 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
- TABLE 26: Europe Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- FRANCE
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 29: France Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: France Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 31: France 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- GERMANY
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 32: Germany Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Germany Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 34: Germany 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- ITALY
- TABLE 35: Italy Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Italy Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 37: Italy 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- UNITED KINGDOM
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 38: UK Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: UK Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 40: UK 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- SPAIN
- TABLE 41: Spain Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Spain Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 43: Spain 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- RUSSIA
- TABLE 44: Russia Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Russia Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 46: Russia 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- REST OF EUROPE
- TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Rest of Europe Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 49: Rest of Europe 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- ASIA-PACIFIC
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 51: Asia-Pacific Historic Review for Asthma Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 52: Asia-Pacific 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
- TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Asia-Pacific Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 55: Asia-Pacific 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- AUSTRALIA
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 56: Australia Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Australia Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 58: Australia 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- INDIA
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 59: India Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: India Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 61: India 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- SOUTH KOREA
- TABLE 62: South Korea Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: South Korea Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 64: South Korea 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Rest of Asia-Pacific Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- LATIN AMERICA
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 68: Latin America Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 69: Latin America Historic Review for Asthma Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 70: Latin America 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
- TABLE 71: Latin America Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Latin America Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 73: Latin America 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- ARGENTINA
- TABLE 74: Argentina Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Argentina Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 76: Argentina 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- BRAZIL
- TABLE 77: Brazil Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Brazil Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 79: Brazil 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- MEXICO
- TABLE 80: Mexico Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Mexico Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 82: Mexico 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Rest of Latin America Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 85: Rest of Latin America 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- MIDDLE EAST
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 86: Middle East Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 87: Middle East Historic Review for Asthma Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 88: Middle East 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
- TABLE 89: Middle East Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Middle East Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 91: Middle East 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- IRAN
- TABLE 92: Iran Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Iran Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 94: Iran 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- ISRAEL
- TABLE 95: Israel Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Israel Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 97: Israel 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- SAUDI ARABIA
- TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Saudi Arabia Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 100: Saudi Arabia 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 101: UAE Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: UAE Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 103: UAE 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Rest of Middle East Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 106: Rest of Middle East 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
- AFRICA
- Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 107: Africa Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Africa Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 109: Africa 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
IV. COMPETITION
